The University of Texas MD Anderson Cancer Center is one of the world’s largest and most respected centers devoted exclusively to cancer patient care, research, education and prevention.

The Texas Legislature created MD Anderson in 1941 as part of The University of Texas System. It is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971.

U.S. News & World Report’s “Best Hospitals” survey has ranked MD Anderson the nation’s top hospital for cancer care for 14 of the past 17 years. The institution has been named one of the nation’s top two hospitals for cancer care every year since the survey began in 1990.
IN FY18:

141.6 K PATIENTS
1.5 M OUTPATIENT VISITS
$170.4 M DONATED CARE

$863 M SPENT ON RESEARCH
$5.2 B OPERATING BUDGET
1.2 K CLINICAL TRIALS

7 K TRAINEES
20.3 K EMPLOYEES
3.1 K VOLUNTEERS
At MD Anderson, everything we do revolves around our patients. In Fiscal Year 2018, more than 141,600 people sought the superior care that has made MD Anderson so widely respected — 45,000 of whom were new patients. There were 10,155 patients enrolled in 1,250-plus clinical trials exploring innovative treatments. MD Anderson’s cancer clinical trial program is one of the largest of its kind.

### Clinical Activity FY18

<table>
<thead>
<tr>
<th>Activity</th>
<th>FY18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital admissions</td>
<td>29,118</td>
</tr>
<tr>
<td>Average number of inpatient beds</td>
<td>587</td>
</tr>
<tr>
<td>Outpatient clinic visits, treatments, procedures</td>
<td>1,458,076</td>
</tr>
<tr>
<td>Pathology/laboratory medicine procedures</td>
<td>13,280,436</td>
</tr>
<tr>
<td>Diagnostic imaging procedures</td>
<td>611,190</td>
</tr>
<tr>
<td>Surgery hours</td>
<td>71,462</td>
</tr>
<tr>
<td>Total active clinical research protocols</td>
<td>1,252</td>
</tr>
</tbody>
</table>
Noteworthy

• MD Anderson is accredited by the Joint Commission to ensure patients receive the best and safest health care possible.

• The institution’s world-renowned pathologists correct a new patient’s initial diagnosis from another hospital up to 25 percent of the time.

• MD Anderson’s Moon Shots Program™ is a collaborative effort to more quickly turn scientific discoveries into clinical advances that save patients’ lives. The program has yielded notable discoveries across the spectrum of cancer care, including prevention, early detection and treatment. The program’s 13 Moon Shots™ are disease-focused initiatives targeting 20 types of cancer. The Moon Shots Program also established 10 platforms that provide unique expertise, technical capabilities and novel infrastructure to support the program’s team-science approach.

• So far, the Moon Shots Program has received $464 million in private philanthropic commitments.

• The nursing program holds the American Nurses Credentialing Center’s Magnet Nursing Services Recognition status, which recognizes health care organizations for quality patient care, nursing excellence and innovations in nursing practice.

• MD Anderson has more full-time registered nurses than most hospitals nationwide, and the most of any hospital in Texas, as well as the most among U.S. cancer centers.

• The institution has the largest group of advanced practice providers specializing in oncology.
• As part of the MD Anderson Oncology Program at Lyndon B. Johnson Hospital, a team of MD Anderson doctors provides cancer care to underserved Texans in collaboration with Harris Health System. MD Anderson provided more than $170.4 million in uncompensated cancer care in FY18.

• MD Anderson’s Adolescent and Young Adult Oncology Program supports cancer patients ages 15 to 29 with access to guidance and support services in the areas of genetics, oncofertility, psychosocial support and survivorship.

• The Enhanced Recovery Program (ERP) has 19 multidisciplinary care teams that work with patients before, during and after surgery to get them through their surgery and recovery process much quicker and with better outcomes. MD Anderson’s ERP model has allowed the division of Surgery to lower the average length of stay from 7½ days to 4½ days, and enabled some teams to reduce patients’ opioid use by 70 percent.

• A volunteer workforce composed of 1,099 on-site, trained volunteers and 2,034 off site myCancerConnection trained survivor volunteers contributed 117,993 hours of service in FY18.

• Houston-area locations in Katy, League City, Sugar Land and The Woodlands provide convenient access to the institution’s renowned multidisciplinary care as well as a range of supportive services and access to clinical trials. Currently, about 15 percent of new patients start their care at one of these locations.

• MD Anderson League City is located in a new four-story, 200,000-square-foot facility that is home to a unique clinical collaboration with The University of Texas Medical Branch that was established to provide more efficient and improved health care for Texans.
At MD Anderson, crucial scientific knowledge gained in the laboratory is rapidly translated into clinical care. In FY18, MD Anderson invested almost $863 million in research, a 17% increase in the past five years.

**Sources of Research Expenditures**

<table>
<thead>
<tr>
<th>Source</th>
<th>FY18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Private industry grants and contracts</td>
<td>$141,656,018</td>
</tr>
<tr>
<td>Philanthropy and foundations</td>
<td>$171,352,085</td>
</tr>
<tr>
<td>State funding allocated for research</td>
<td>$84,280,433</td>
</tr>
<tr>
<td>Federal grants and contracts</td>
<td>$173,899,855</td>
</tr>
<tr>
<td>Internal funding allocated for research</td>
<td>$291,693,993</td>
</tr>
<tr>
<td><strong>Total research expenditures</strong></td>
<td><strong>$862,882,384</strong></td>
</tr>
</tbody>
</table>

**Noteworthy**

- Jim Allison, Ph.D., chair of Immunology and executive director of the Moon Shots Program’s immunotherapy platform, was awarded the 2018 Nobel Prize in Physiology or Medicine in recognition of his invention of immune checkpoint blockade as a treatment for cancer. The revolutionary cancer treatment frees the immune system to attack tumors.
• MD Anderson received the most grants from the National Cancer Institute in FY2018, and was No. 2 in overall NCI funding for the year.

• In the past year, the institution was awarded $72.2 million by the Cancer Prevention and Research Institute of Texas (CPRIT). Since 2009, CPRIT has awarded $2.17 billion to fund the fight against cancer, of which MD Anderson has received $428 million, or nearly 20 percent.

• Almost $195 million in philanthropic gifts went to research conducted in all mission areas.

• Two studies led by MD Anderson researchers showed that minimally invasive radical hysterectomy is associated with higher recurrence rates and worse overall survival compared to abdominal radical hysterectomy for women with early-stage cervical cancer. Based on the results, minimally invasive radical hysterectomies are no longer offered to MD Anderson cervical cancer patients, and national treatment guidelines are expected to soon reflect these changes.

• An engineered form of the common cold virus, designed to seek out and attack glioblastoma cells, achieved a progression-free survival of more than 3 years in 20% of patients, according to results of a Phase I study. The clinical trial injected the altered virus directly into the tumors of 25 patients with recurrent glioblastoma, a group that typically survives just six months.

• Combination immunotherapy treatment successfully shrunk melanoma brain metastases in more than half of patients, according to the results of a Phase II clinical trial. Brain metastases often are a disabling neurologic condition in patients with stage 4 melanoma and frequently result in fatalities in just 4-5 months. The results of the clinical trial challenge the standard of care, suggesting that combination immunotherapy may be initiated early for these patients rather than first treating the metastases with radiation.
• Researchers in MD Anderson’s Leukemia department played central roles in the studies of two drugs, glasdegib and venetoclax, approved in November 2018 by the Food and Drug Administration for treating acute myeloid leukemia in patients not eligible for intensive chemotherapy.

• A randomized, Phase III clinical trial showed that the PARP inhibitor talazoparib extended progression-free survival and improved quality-of-life measures over chemotherapy for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. The trial, known as EMBRACA, led to FDA approval of talazoparib for patients with this type of metastatic breast cancer.

• Through MD Anderson Cancer Network®, the institution has partnered with The Queen’s Cancer Center in Honolulu to launch four clinical trials that focus on multiple cancer types, including breast and ovarian cancers. The diversity of the patient population that Queen’s serves results in studies that are more comprehensive.
MD Anderson’s total revenue in FY18 was $5.2 billion. Of that total, only 4.0% was general revenue appropriated by the State of Texas.

<table>
<thead>
<tr>
<th>Sources of Revenue</th>
<th>Amount</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net patient revenue</td>
<td>$4,084.1</td>
<td>78.2%</td>
</tr>
<tr>
<td>Restricted grants and contracts, philanthropy</td>
<td>$498</td>
<td>9.5%</td>
</tr>
<tr>
<td>State-appropriated general revenue</td>
<td>$120.3</td>
<td>4%</td>
</tr>
<tr>
<td>Investment and other non-operating income</td>
<td>$44.2</td>
<td>5.1%</td>
</tr>
<tr>
<td>Other income</td>
<td>$210.1</td>
<td>2.3%</td>
</tr>
<tr>
<td>Auxiliary income</td>
<td>$268.2</td>
<td>0.8%</td>
</tr>
</tbody>
</table>

The institution generates $26.8 additional dollars for cancer patient care, education and research for each $1 of general revenue, and $39.6 dollars in research support for every $1 in general revenue from the state for research.
Close to 7,100 trainees, including physicians, scientists, nurses and allied health professionals, took part in educational programs at MD Anderson in FY18. The institution’s School of Health Professions awards degrees in 10 bachelor’s programs and two master’s programs in allied health disciplines. In collaboration with the UT Health Science Center at Houston, MD Anderson awards M.S., Ph.D. and M.D./Ph.D. degrees at the MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences.

**Education Profile**

<table>
<thead>
<tr>
<th>Category</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical residents, fellows</td>
<td>1,775</td>
</tr>
<tr>
<td>Research trainees</td>
<td>1,791</td>
</tr>
<tr>
<td>Observers, visitors, special programs</td>
<td>831</td>
</tr>
<tr>
<td>Nursing trainees</td>
<td>1,440</td>
</tr>
<tr>
<td>Student programs participants</td>
<td>888</td>
</tr>
<tr>
<td>School of Health Professions students</td>
<td>357</td>
</tr>
<tr>
<td><strong>Total trainees</strong></td>
<td><strong>7,082</strong></td>
</tr>
</tbody>
</table>
Noteworthy

- There are 83 GME programs accredited by the Accreditation Council for Graduate Medical Education (27), American Dental Association (1), or approved by the Texas Medical Board (55).

- MD Anderson is accredited by the Accreditation Council for Graduate Medical Education as a Sponsoring Institution and has maintained Continued Accreditation status for more than 20 years.

- MD Anderson offers nursing training and education programs that include:
  - The Graduate Nurse Residency Program, which provides registered nurses with orientation and transition to practice in five specialty tracks: clinical and research nursing, nursing resource pool, ambulatory treatment center and the operating room.
  - Post Graduate Fellowship in Oncology Nursing, which prepares and trains advanced practice nurses to function as clinical experts in the complex environment of oncology care.
MD Anderson continues to set the standard in cancer prevention research and the translation of new knowledge into innovative, multidisciplinary care.

The institution’s Cancer Prevention and Population Sciences division is dedicated to:

- Ending cancer through pioneering research into the roles that biologic, genetic, environmental, economic, behavioral and social factors play in cancer development.

- Investigating various types of interventions to prevent or reduce cancer risk.

- Improving cancer care delivery, safety, availability and affordability.

Through the Duncan Family Institute for Cancer Prevention and Risk Assessment, the division is investing in promising new research directions and integrating basic research and clinical studies to accelerate their translation from the lab to the clinic to the community.

The Lyda Hill Cancer Prevention Center provides cancer risk assessments; screening exams based on genetics, age and gender; and personalized risk-reduction strategies, including lifestyle-based interventions and chemoprevention.
Noteworthy

• In FY18, there were 47,310 patient visits in the Lyda Hill Cancer Prevention Center.

• Over 5,000 patients received tobacco cessation services through the Tobacco Treatment Program in FY18.

• Thanks to Eliminate Tobacco Use, a joint initiative of The University of Texas System and MD Anderson, all 14 UT System institutions are tobacco-free, protecting 221,000 students, 100,000 staff and more than 199,000 total lives covered under the UT System’s health insurance plan. MD Anderson’s EndTobacco™ program, an evidence-based tobacco-control initiative, played an instrumental role in the creation of Eliminate Tobacco Use.

• 27,874 children received tobacco prevention education through the Youth and Family Cancer Prevention Program. Community Relations and Education provided tobacco prevention education to 13,970 children and teens in FY18.

• 50,000 classrooms nationwide potentially reaching 1.5 million children received school-based education about sun safety.

• MD Anderson’s Be Well Communities™ is a community approach to cancer prevention and control to promote wellness and reduce modifiable cancer risk factors. MD Anderson leads Be Well™ Baytown — the inaugural Be Well Community — with the support
of more than 16 collaborating organizations focused on the five target health areas of diet, physical activity, preventive care, tobacco control and ultraviolet radiation exposure.

- With the support of the cancer prevention and control platform, MD Anderson’s HPV-Related Cancers Moon Shot™ is working to identify practical solutions and strategies to enhance awareness, improve vaccination rates and ultimately reduce incidence and mortality of HPV-related cancers.

- MD Anderson researchers, together with collaborators from Mozambique, Brazil and the United States, have been awarded a $5.1 million grant to evaluate innovative approaches to increase screening and prevention of cervical cancers in Mozambique, which has some of the highest rates of cervical cancer in the world. The grant was awarded by the Partnerships for Enhanced Engagement in Research (PEER) program.
At the nation’s No. 1 hospital for cancer care (U.S. News and World Report), almost 20,400 employees are working to advance patient care, research and education. Some of the world’s most recognized researchers and clinicians are part of this elite team that is Making Cancer History®.

**Noteworthy**

- Forbes recognized MD Anderson as one of “America’s Best Employers” for 2018. Forbes also featured the institution on its list of “Best Employers for Diversity.”

- MD Anderson’s commitment to those who have served in our nation’s military earned it a spot on the 2018 “Best for Vets” employers list.

- MD Anderson was chosen for the 2019 Best Places To Work list by Glassdoor, a job and recruiting web site.

- MD Anderson President Peter WT Pisters, M.D., was named a Top CEO for 2018 by Glassdoor. Pisters was the only Houston leader on the 2018 Glassdoor Employees’ Choice Awards list of CEOs of large U.S. organizations.

- Padmanee Sharma, M.D., Ph.D., was named the 2018 recipient of the Julie and Ben Rogers Award for Excellence in Research for her work in using the immune system to fight cancer.
• Frances MacDonald, a clinical nurse in MD Anderson’s GI-Colorectal Center, received the 2018 Brown Foundation Award for Excellence in Oncology Nursing.

• The institution’s faculty is one of the most esteemed in the nation, including eight members of the National Academy of Medicine, six National Academy of Sciences members, four Academy of Arts and Sciences fellows and 46 American Association for the Advancement of Science fellows.
In addition to the Texas Medical Center campus and research campuses in Bastrop and Smithville, Texas, MD Anderson provides cancer care at several convenient locations throughout Greater Houston. MD Anderson Cancer Network\textsuperscript{®} advances our mission of eliminating cancer by collaborating with community hospitals and health systems to improve the quality of care nationwide.

**Houston-area locations**

- Texas Medical Center
- Katy
- League City
- Sugar Land
- The Woodlands
- Bellaire (imaging and blood work)
- Memorial City (surgery)
- West Houston (imaging and blood work)
- The Woman’s Hospital of Texas (gynecologic cancer care)
- Selected Memorial Hermann locations (breast imaging and diagnostic services)
MD Anderson Cancer Network

PARTNERS

- Banner MD Anderson Cancer Center (Gilbert, Arizona)
- MD Anderson Cancer Center at Cooper (Camden, New Jersey)
- Baptist MD Anderson Cancer Center (Jacksonville, Florida)
- Scripps MD Anderson Cancer Center (San Diego)
- UT Health San Antonio MD Anderson Cancer Center
- UT Health North Campus Tyler MD Anderson Cancer Center

PARTNER EXTENSIONS

- Banner MD Anderson Cancer Center at North Colorado Medical Center (Greeley, Colorado)
- Banner MD Anderson Cancer Center at McKee Medical Center (Loveland, Colorado)

CERTIFIED MEMBERS

- 17 health systems and hospitals in 15 states

ASSOCIATES

- Hospital Israelita Albert Einstein (São Paulo)
- MD Anderson Cancer Center Madrid
- Vehbi Koc Foundation American Hospital (Istanbul)

AFFILIATES

- MD Anderson Radiation Treatment Center at American Hospital (Istanbul)
- Presbyterian MD Anderson Radiation Treatment Center (Albuquerque, New Mexico)
Mission
The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

Vision
We shall be the premier cancer center in the world, based on the excellence of our people, our research-driven patient care and our science.

We are Making Cancer History®.

Core Values
Caring: By our words and actions, we create a caring environment for everyone.

Integrity: We work together to merit the trust of our colleagues and those we serve.

Discovery: We embrace creativity and seek new knowledge.